Blinatumomab is associated with better post-transplant outcome than chemotherapy in children with high-risk first-relapse B-cell acute lymphoblastic leukemia irrespective of the conditioning regimen

Authors

Angela Bruno
Christina Peters (ORCID: https://orcid.org/0000-0003-0369-8515)
Franco Locatelli (ORCID: https://orcid.org/0000-0002-7976-3654)
Gerhard Zugmaier (ORCID: https://orcid.org/0000-0001-6879-2671)
Christin Linderkamp
Carmelo Rizzari (ORCID: https://orcid.org/0000-0002-4828-3893)
Arend von Stackelberg (ORCID: https://orcid.org/0000-0002-8103-2631)
Yi Zeng (ORCID: https://orcid.org/0000-0002-4172-1467)
Alessandra Brescianini

Institutions

Amgen (United States) (US)
Medizinische Hochschule Hannover (DE)
Amgen (Germany) (DE)
Bambino Gesù Children's Hospital (IT)
St Anna Children's Hospital (AT)
Rotkreuzklinikum München (DE)
University of the Sacred Heart (JP)
Biogen (Italy) (IT)
University of Milano-Bicocca (IT)
Charité - Universitätsmedizin Berlin (DE)

Publication Details

Journal: Haematologica
Published: 2024-09-05
DOI: https://doi.org/10.3324/haematol.2024.285837
Citations: 2
Primary Topic: Acute Lymphoblastic Leukemia research
Type: article
Field-Weighted Citation Impact: 1.09

Funders

Amgen

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Blinatumomab is associated with better post-transplant outcome than chemotherapy in children with high-risk first-relapse B-cell acute lymphoblastic leukemia irrespective of the conditioning regimen

Angela Bruno, Christina Peters, Franco Locatelli, Gerhard Zugmaier et al.

Sep 5, 2024

2 citations

Haematologica

Acute Lymphoblastic Leukemia research

1.09

article

Blinatumomab is associated with better post-transplant outcome than chemotherapy in children with high-risk first-relapse B-cell acute lymphoblastic leukemia irrespective of the conditioning regimen

Angela Bruno, Christina Peters, Franco Locatelli, Gerhard Zugmaier, Christin Linderkamp, Carmelo Rizzari, Arend von Stackelberg, Yi Zeng, Alessandra Brescianini

September 5, 2024article en

2 citations

Abstract

No abstract available for this paper.

HaematologicaVol. 110(1)

Amgen (United States) (US), Medizinische Hochschule Hannover (DE), Amgen (Germany) (DE), Bambino Gesù Children's Hospital (IT), St Anna Children's Hospital (AT), Rotkreuzklinikum München (DE), University of the Sacred Heart (JP), Biogen (Italy) (IT), University of Milano-Bicocca (IT), Charité - Universitätsmedizin Berlin (DE)

Amgen

Good health and well-being

Openalex Percentile: Top 21%

Acute Lymphoblastic Leukemia research

1.09

DOI Open Access PDF OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Blinatumomab is associated with better post-transplant outcome than chemotherapy in children with high-risk first-relapse B-cell acute lymphoblastic leukemia irrespective of the conditioning regimen — Angela Bruno, Christina Peters, et al. · Haematologica (2024) | TGRS Research Map | TGRS